The 340B Drug Pricing Program gives discounts to qualifying hospitals and healthcare entities for certain prescription drugs under the condition that any of those savings will be used to help low-income and uninsured patients. Patients in your state with conditions like cancer, HIV, and arthritis depend on this federal program to access affordable healthcare at 340B facilities. However, the data tell us some facilities are using the 340B program for profit rather than to help patients in need. The 340B program today lacks the level of oversight and transparency needed to ensure it is helping already vulnerable patients afford their care.
Tell your state Attorney General: Increase Transparency of 340B to Protect Vulnerable Patients.
Send a letter to your State Attorney General RIGHT NOW to urge them to bring greater transparency to the federal 340B Program. The money that qualifying 340B entities save through the program should be reinvested in serving eligible patients — not profits. Ask your State Attorney General to ensure that 340B savings are going toward improving access to care for America's most vulnerable patient populations.
[SUBJECT] ACT NOW: Ensure Federal 340B Program Provides Affordable Healthcare for Patients In Your State
Dear [State Attorney General]:
I am writing to you today to bring attention to abuses surrounding the 340B Drug Pricing Program and ask for your help in protecting patients – our family members, friends, and neighbors. The federal 340B program was designed to help low-income and uninsured patients access the care and medications they need to manage conditions such as cancer, HIV, and arthritis. Unfortunately, the 340B program today lacks the level of oversight and transparency that is needed to ensure that savings from reduced drug prices are actually being passed down to needy patients.
The 340B Program allows qualifying hospitals and clinics to purchase prescription drugs at a significant discount and pass those discounts on to vulnerable and qualifying patients. Unfortunately, without any legal or regulatory obligation to pass savings on to patients, there is no way to know if patients are benefiting from those drug discounts. Today, evidence suggests that qualifying hospitals and clinics may be abusing the 340B program and harming patients in the process. 340B program sales grew over 400% from 2012 to 2019 without a proportionate increase in patient treatment access, indicating that 340B hospitals, clinics, and pharmacies are profiting at the expense of patients.
Congress meant for 340B to expand treatment access for vulnerable, low-income patients, not increase profits for hospitals and clinics.
I urge you to take action to bring greater oversight and transparency to the 340B Drug Pricing Program to ensure patients are actually benefiting from the savings. Please act to ensure hospitals in the program are being held accountable for passing prescription drug discounts on to patients who rely on charity care to maintain their health.
Thank you for your leadership to protect citizens in our great state and your attention on this critical patient issue.